30/09/2024Published by Fondazione Gianni Bonadonna at 30/09/2024Categories Events UncategorizedA new predictive biomarker of immunotherapy benefit in triple-negative breast cancer was validated in the NeoTRIP trial
23/09/2024Published by Fondazione Gianni Bonadonna at 23/09/2024Categories Events UncategorizedInavolisib plus palbociclib and endocrine therapy in ER+/HER2- advanced breast cancer
16/09/2024Published by Fondazione Gianni Bonadonna at 16/09/2024Categories Events UncategorizedSafety and efficacy of imlunestrant in ER+/HER2- advanced breast cancer
09/09/2024Published by Fondazione Gianni Bonadonna at 09/09/2024Categories Events UncategorizedHow many immunotherapy trials in breast cancer translate into positive phase III trials?
02/09/2024Published by Fondazione Gianni Bonadonna at 02/09/2024Categories Events UncategorizedEfficacy of osimertinib in EGFR-mutated non-small-cell lung cancer
26/08/2024Published by Fondazione Gianni Bonadonna at 26/08/2024Categories Events UncategorizedThe sequential use of sacituzumab govitecan as a promising strategy in breast cancer
05/08/2024Published by Fondazione Gianni Bonadonna at 05/08/2024Categories Events UncategorizedEfficacy of adjuvant pembrolizumab in renal-cell carcinoma
29/07/2024Published by Fondazione Gianni Bonadonna at 29/07/2024Categories Events UncategorizedTisotumab vedotin for recurrent cervical cancer
22/07/2024Published by Fondazione Gianni Bonadonna at 22/07/2024Categories Events UncategorizedA HER2-targeting antibody-drug conjugate in metastatic breast cancer
